Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)
May 9 Biohaven Pharmaceutical Holding Company Ltd:
BRIEF-Biohaven Announces Robust Clinical Data With Single Dose Rimegepant That Defines Acute And Durable Benefits To Patients
April 22 Biohaven Pharmaceutical Holding Company Ltd:
Biohaven Pharmaceutical Holding said its treatment for acute migraine cleared two late-stage studies, but investors worried about its commercial viability as the efficacy data failed to distinguish from Allergan's rival treatment.
March 26 Biohaven Pharmaceutical Holding Co Ltd said its migraine treatment met the main goals in two late-stage studies but the efficacy data failed to differentiate when compared with rival treatments in a crowded field.
BRIEF-Biohaven Says Achieved Both Co-Primary Regulatory Endpoints In Two Pivotal Phase 3 Trials Of Rimegepant
March 26 Biohaven Pharmaceutical Holding Company Ltd:
- Your Daily Pharma Scoop: FibroGen Fast Tracked, Dr. Reddy's Entry, Bristol-Myers Succeeds
- Your Daily Pharma Scoop: Biohaven In Pivotal Stage, Merck Trial Positive, FDA Waives EyeGate
- Stocks To Watch: Tariffs Don't Take Holidays
- ElectroCore Readies $65 Million U.S. IPO Plans
- Your Daily Pharma Scoop: Biohaven Updates, MEIP Offering, Kite European Expansions
- Institutional Top Ideas Series: Ra Capital Management